Yes, the Chinese industry effort will no doubt be interesting... and I have a biotech with a Japanese partner that might license for China... I like that model better because I expect the Japanese will be more crafty than most American firms in China. Plus, it’s an oblique entry, if it happens. With all the tension right now, a direct partnership seems likely to be highly politicized.
News 
Market Data 
Discover 
AI
